MA51524A - COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES - Google Patents

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES

Info

Publication number: MA51524A
Authority: MA; Morocco
Prior art keywords: compositions; compounds; treatment; methods; diseases involving
Prior art date: 2018-01-05

Inventor

Oleg Andreev

Johanna Marie Csengery

Don Engleman

Dalton King

Daniel Richard Marshall

Yana Reshetnyak

Robert A Volkmann

Original Assignee

Cybrexa 1 Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-01-05

Filing date

2019-01-04

Publication date

2020-11-11

2019-01-04Application filed by Cybrexa 1 IncfiledCriticalCybrexa 1 Inc

2020-11-11Publication of MA51524ApublicationCriticalpatent/MA51524A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA051524A2018-01-052019-01-04 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUESMA51524A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862613931P	2018-01-05	2018-01-05
US201862758264P	2018-11-09	2018-11-09

Publications (1)

Publication Number	Publication Date
MA51524Atrue MA51524A (en)	2020-11-11

Family

ID=65411925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA051524AMA51524A (en)	2018-01-05	2019-01-04	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES

Country Status (18)

Country	Link
US (2)	US10933069B2 (en)
EP (1)	EP3735297A1 (en)
JP (2)	JP7356450B2 (en)
KR (1)	KR20200121800A (en)
CN (1)	CN111989137A (en)
AU (1)	AU2019205325A1 (en)
BR (1)	BR112020013672A2 (en)
CA (1)	CA3088858A1 (en)
CL (1)	CL2020001797A1 (en)
CR (1)	CR20200334A (en)
EC (1)	ECSP20046463A (en)
IL (1)	IL275754A (en)
MA (1)	MA51524A (en)
MX (1)	MX2020007060A (en)
PE (1)	PE20211305A1 (en)
PH (1)	PH12020551043A1 (en)
TW (1)	TWI820077B (en)
WO (1)	WO2019136298A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3066384A1 (en)*	2017-06-09	2018-12-13	Rhode Island Council On Postsecondary Education	Linked and other ph-triggered compounds
US10633383B2 (en)	2018-01-05	2020-04-28	Ac Immune Sa	Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
MA51524A (en)	2018-01-05	2020-11-11	Cybrexa 1 Inc	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES
PE20220563A1 (en)	2019-07-10	2022-04-13	Cybrexa 2 Inc	PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
AU2020311925A1 (en)	2019-07-10	2022-02-03	Cybrexa 3, Inc.	Peptide conjugates of microtubule-targeting agents as therapeutics
CN112939966B (en)*	2019-12-10	2023-03-24	武汉光谷亚太医药研究院有限公司	Pyrimidine derivatives, their preparation and use
CN115298198A (en)	2020-01-21	2022-11-04	上海盟科药业股份有限公司	Novel compounds and compositions for targeted therapy of kidney-related cancers
CN111285936A (en)*	2020-03-11	2020-06-16	北京双赢科创生物科技有限公司	Acid-sensitive nanopeptides targeting tumors and their applications
MX2023008146A (en)	2021-01-08	2023-07-24	Cybrexa 2 Inc	Process for preparing a conjugate linking moiety.
WO2022155172A1 (en)	2021-01-13	2022-07-21	Cybrexa 3, Inc.	Peptide conjugates of therapeutics
CN115137818B (en)*	2021-03-31	2023-06-27	华南师范大学	Glutathione activated photosensitizer-chemotherapeutic agent integrated molecular prodrug and application thereof
US20240279225A1 (en)	2021-04-08	2024-08-22	Board Of Regents, The University Of Texas System	Compounds and methods for theranostic targeting of parp activity
WO2022232808A1 (en)	2021-04-29	2022-11-03	Cybrexa 2, Inc.	Dosing regimens of peptide conjugates of topoisomerase i inhibitors
KR102677962B1 (en)*	2022-03-02	2024-06-25	고려대학교 산학협력단	Improved method of preparing rucaparib
CN116640229B (en)*	2023-04-10	2024-01-30	中国人民解放军总医院第五医学中心	Construction and application of a low-pH targeted CAR-T cell
CN117843713A (en)*	2023-12-18	2024-04-09	上海亲合力生物医药科技股份有限公司	Kinase inhibitor based on tumor microenvironment activation, composition and application

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ30398A3 (en)*	1995-08-02	1998-06-17	Newcastle University Ventures Limited	Benzimidazole compounds, pharmaceutical preparation in which the compounds are comprised and use of the compounds as chemotherapeutic agents
MY132496A (en)*	1998-05-11	2007-10-31	Vertex Pharma	Inhibitors of p38
WO2000026192A1 (en)	1998-11-03	2000-05-11	Basf Aktiengesellschaft	Substituted 2-phenylbenzimidazoles, the production thereof and their use
RS50031B (en)	1999-01-11	2008-11-28	Agouron Pharmaceuticals Inc.,	TRICYCLIC POLY INHIBITORS (ADP-Ribose) POLYMERASE
DE19920936A1 (en)	1999-05-07	2000-11-09	Basf Ag	Heterocyclically substituted benzimidazoles, their preparation and use
ECSP003637A (en)	1999-08-31	2002-03-25	Agouron Pharma	TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES
WO2001041534A2 (en)	1999-12-13	2001-06-14	Eli Lilly And Company	Pseudomycin phosphate prodrugs
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GEP20074230B (en)	2002-03-20	2007-11-12	Bristol Myers Squibb Co	Phosphate prodrugs of fluorooxindoles
JP4500161B2 (en)	2002-04-30	2010-07-14	クドスファーマシューティカルズリミテッド	Phthalazinone derivatives
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
MXPA05010563A (en)	2003-03-31	2005-11-23	Pfizer	Salts of tricyclic inhibitors of poly(adp-ribose) polymerases.
GB0317466D0 (en)	2003-07-25	2003-08-27	Univ Sheffield	Use
ATE454893T1 (en)*	2003-07-25	2010-01-15	Cancer Rec Tech Ltd	TRICYCLIC PARP INHIBITORS
PT1684736E (en)	2003-12-01	2011-11-10	Cancer Res Inst	Dna damage repair inhibitors for treatment of cancer
EP1793830A2 (en)	2004-09-22	2007-06-13	Pfizer, Inc.	Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
RU2355691C2 (en)	2004-09-22	2009-05-20	Пфайзер Инк.	Polymorphous and amorphous forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepine[5,4,3-cd]indol-6-on phosphate
SI1794163T1 (en)	2004-09-22	2010-04-30	Pfizer	Method of preparing poly(adp-ribose) polymerases inhibitors
EP1846014B1 (en)	2005-01-18	2012-10-24	The Board of Governors for Higher Education State of Rhode Island and Providence Plantations	Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2007041357A1 (en)	2005-09-29	2007-04-12	Abbott Laboratories	1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
DK2338487T3 (en)*	2006-01-17	2013-12-09	Abbvie Bahamas Ltd	Combination therapy with PARP inhibitors
JP2009536526A (en)	2006-05-04	2009-10-15	ジェネンテック・インコーポレーテッド	Methods and compositions related to ZPA polypeptides
UY30639A1 (en)	2006-10-17	2008-05-31	Kudos Pharm Ltd	SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
WO2008084261A1 (en)	2007-01-10	2008-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008114114A2 (en)	2007-03-16	2008-09-25	Pfizer Products Inc.	Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
US8067613B2 (en)	2007-07-16	2011-11-29	Abbott Laboratories	Benzimidazole poly(ADP ribose)polymerase inhibitors
JP5579170B2 (en)*	2008-06-05	2014-08-27	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist
US9353140B2 (en)	2009-11-25	2016-05-31	Academia Sinica	BQC-G, a tumor-selective anti-cancer prodrug
MX343383B (en)	2010-02-12	2016-11-03	Pfizer Inc *	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl }-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one.
CA2805387C (en)*	2010-07-13	2021-10-26	Rhode Island Board Of Governors For Higher Education	Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
AU2011289279B2 (en)*	2010-08-13	2016-11-03	University Of Rhode Island Board Of Trustees	Liposome compositions and methods of use thereof
IL290330B2 (en)	2013-12-19	2023-09-01	Seagen Inc	Methylene carbamate linkers for use with targeted-drug conjugates
CN105917007A (en)	2014-01-16	2016-08-31	克洛维斯肿瘤有限公司	Use of PARP inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JOP20200096A1 (en)	2014-01-31	2017-06-16	Children’S Medical Center Corp	Antibody molecules to tim-3 and uses thereof
US20170151339A1 (en)*	2014-06-30	2017-06-01	Tarveda Therapeutics, Inc.	Targeted conjugates and particles and formulations thereof
KR102803917B1 (en)	2014-08-22	2025-05-07	파르마＆ 슈바이츠 게엠베하	High Dosage Strength Tablets of Rucaparib
PL3204018T3 (en)*	2014-10-07	2022-01-03	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
JO3705B1 (en)	2014-11-26	2021-01-31	Bayer Pharma AG	Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
KR102407261B1 (en)	2015-02-27	2022-07-06	서울대학교산학협력단	Nanoformulated Anticancer Drug and Process for Preparing the Same
MA43354A (en)*	2015-10-16	2018-08-22	Genentech Inc	CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
BR112018010650A8 (en)	2015-11-24	2019-02-26	Theravance Biopharma R&D Ip Llc	prodrugs of a compound jak inhibitor for the treatment of gastrointestinal inflammatory disease
KR102498258B1 (en)	2016-01-20	2023-02-10	삼성디스플레이 주식회사	Display device
US20170267727A1 (en)*	2016-03-04	2017-09-21	Lehigh University	Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
GB201608885D0 (en)*	2016-05-20	2016-07-06	Univ Birmingham	Treatment
WO2017210608A1 (en)	2016-06-02	2017-12-07	Yale University	Compositions and methods for targeting and treating homologous recombination-deficient tumors
CN110312549B (en)*	2016-12-19	2021-06-29	莫尔豪斯医学院	Compositions and methods for treating disease by inhibiting exosome release
CA3066384A1 (en)	2017-06-09	2018-12-13	Rhode Island Council On Postsecondary Education	Linked and other ph-triggered compounds
MA51524A (en)	2018-01-05	2020-11-11	Cybrexa 1 Inc	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES
CN109232719B (en)	2018-09-21	2021-06-29	中国科学院理化技术研究所	A pH-responsive antimicrobial peptide and its preparation method and application
AU2020311925A1 (en)	2019-07-10	2022-02-03	Cybrexa 3, Inc.	Peptide conjugates of microtubule-targeting agents as therapeutics
PE20220563A1 (en)	2019-07-10	2022-04-13	Cybrexa 2 Inc	PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS

2019
- 2019-01-04MAMA051524Apatent/MA51524A/enunknown
- 2019-01-04CACA3088858Apatent/CA3088858A1/enactivePending
- 2019-01-04BRBR112020013672-7Apatent/BR112020013672A2/enunknown
- 2019-01-04KRKR1020207022639Apatent/KR20200121800A/ennot_activeCeased
- 2019-01-04CRCR20200334Apatent/CR20200334A/enunknown
- 2019-01-04AUAU2019205325Apatent/AU2019205325A1/ennot_activeAbandoned
- 2019-01-04PEPE2020000907Apatent/PE20211305A1/enunknown
- 2019-01-04TWTW108100452Apatent/TWI820077B/ennot_activeIP Right Cessation
- 2019-01-04MXMX2020007060Apatent/MX2020007060A/enunknown
- 2019-01-04WOPCT/US2019/012413patent/WO2019136298A1/ennot_activeCeased
- 2019-01-04USUS16/240,438patent/US10933069B2/enactiveActive
- 2019-01-04EPEP19705248.3Apatent/EP3735297A1/ennot_activeWithdrawn
- 2019-01-04JPJP2020557122Apatent/JP7356450B2/enactiveActive
- 2019-01-04CNCN201980012818.6Apatent/CN111989137A/enactivePending
2020
- 2020-06-30ILIL275754Apatent/IL275754A/enunknown
- 2020-07-03CLCL2020001797Apatent/CL2020001797A1/enunknown
- 2020-07-03PHPH12020551043Apatent/PH12020551043A1/enunknown
- 2020-08-04ECECSENADI202046463Apatent/ECSP20046463A/enunknown
- 2020-10-28USUS17/082,992patent/US12427157B2/enactiveActive
2023
- 2023-09-22JPJP2023158930Apatent/JP2024009819A/enactivePending

Also Published As

Publication number	Publication date
CA3088858A1 (en)	2019-07-11
KR20200121800A (en)	2020-10-26
TWI820077B (en)	2023-11-01
BR112020013672A2 (en)	2020-12-01
CN111989137A (en)	2020-11-24
EP3735297A1 (en)	2020-11-11
JP2024009819A (en)	2024-01-23
US20210299137A1 (en)	2021-09-30
US10933069B2 (en)	2021-03-02
PH12020551043A1 (en)	2021-09-06
WO2019136298A1 (en)	2019-07-11
JP7356450B2 (en)	2023-10-04
TW201938540A (en)	2019-10-01
CR20200334A (en)	2021-03-09
US12427157B2 (en)	2025-09-30
ECSP20046463A (en)	2020-12-31
CL2020001797A1 (en)	2021-01-29
MX2020007060A (en)	2020-11-11
JP2021510173A (en)	2021-04-15
IL275754A (en)	2020-08-31
PE20211305A1 (en)	2021-07-20
US20190209580A1 (en)	2019-07-11
AU2019205325A1 (en)	2020-08-13

Publication	Publication Date	Title
MA51524A (en)	2020-11-11	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES
MA51200A (en)	2020-10-07	NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA55325A (en)	2022-04-27	COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES
MA55974A (en)	2022-03-23	TRIARYL COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES
EP3411380A4 (en)	2020-01-22	COMPOUNDS FOR THE TREATMENT OF EYE DISORDERS OR DISEASES
MA56019A (en)	2022-04-06	NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3448875A4 (en)	2020-04-08	COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA41841A (en)	2018-02-06	ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
EP3411080A4 (en)	2019-08-14	COMPOUNDS AND METHODS FOR TREATING RNA MEDIATED DISEASES
MA52873A (en)	2021-04-21	NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3429605A4 (en)	2019-09-18	THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
EP3802539C0 (en)	2023-09-20	NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MA49141A (en)	2020-03-25	PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
EP3773632A4 (en)	2022-05-18	METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS
MA54077A (en)	2021-09-15	POLYTHERAPY FOR THE TREATMENT OF BLOOD DISEASES
MA52415A (en)	2021-01-06	TRIAZINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NEUROTROPHINS
EP3922264A4 (en)	2024-01-10	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
SG11202007082PA (en)	2020-08-28	Composition used for therapeutic treatment of skin disease
EP3849591A4 (en)	2022-10-12	METHODS AND COMPOSITIONS FOR TREATING DISEASES OF THE SKIN
MA54741A (en)	2021-11-24	THIENYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
MA53817A (en)	2021-08-11	BIPHENYL-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF TYPE IV COLLAGEN DISEASES
EP4000609A4 (en)	2023-07-26	PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES
EP3856198A4 (en)	2022-06-22	LOW INTENSITY TREATMENT OF BLOOD DISORDERS
MA55141A (en)	2021-09-29	CYANOARYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
MA55144A (en)	2021-09-29	NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS

Movatterモバイル変換